clinical trial · NCT01422434
LEO 90105 Ointment in Japanese Subjects With Psoriasis
LEO Pharma·phase3·completed·n = 676
PsoriasisLEO 90105 = calcipotriol + betamethasone dipropionateDovonex® = calcipotriolRinderon® - DP = betamethasone dipropionate
brief summary
The purpose of this study is to compare the efficacy of LEO 90105 ointment applied once daily with Dovonex® ointment applied twice daily and with Rinderon®-DP ointment applied once daily in Japanese subjects with psoriasis vulgaris.
started
Jul 1, 2011
primary completion
Apr 1, 2012
completion
Apr 1, 2012
last updated
Mar 12, 2025
detailed description
LEO 90105 ointment contains both calcipotriol and betamethasone dipropionate. It has been approved for the treatment of psoriasis in more than 60 centres, including most European countries, the US, China, Korea and Taiwan. This trial will investigate its safety and efficacy in the treatment of Japanese subjects with psoriasis.
official title
Efficacy and Safety of LEO 90105 Ointment (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Japanese Subjects With Psoriasis Vulgaris
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol